and in the first European countries for second-line ESCC and first- and second-line non-small cell lung cancer (NSCLC); ...

BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential ...

Krystal Biotech, Inc. (NASDAQ:KRYS) Q3 2024 Earnings Call Transcript November 4, 2024 Krystal Biotech, Inc. beats earnings expectations. Reported EPS is $0.909, expectations were $0.9. Operator: Thank ...

with first data readout expected in summer 2025 European Committee for Medicinal Products for Human Use (CHMP) review of ...

Q3 2024 Earnings Call Transcript November 7, 2024 PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.39, ...

Neuraxpharm and partner Minoryx Therapeutics, meanwhile, were unable to convince the CHMP that they should get conditional approval for PPAR gamma agonist Nezglyal (leriglitazone) as a treatment ...

NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November ...

PTC Therapeutics Inc (PTCT) reports strong Q3 revenue and raises 2024 guidance, while navigating regulatory hurdles and ...

The CHMP has backed approval of Tecvayli for adults with relapsed and refractory multiple myeloma who have received at least three prior therapies – including an immunomodulatory agent ...

PTC Therapeutics sees 2024 revenue $750M-$800M, consensus $734.43M Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

Thank you for standing by, and welcome to the appellate Pharmaceuticals Third Quarter 2024 earnings conference call. At this time, all participants are in a listen only mode. After the speakers' ...